Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Advances in Connective Tissue Disease-Associated Interstitial Lung Disease

Jason Liebowitz, MD, FACR  |  December 1, 2021

ACR Convergence 2021—The past year has been an exciting time for researchers and clinicians focused on the topic of connective tissue disease-associated interstitial lung disease (CTD-ILD), with advances in our understanding of these disorders and newly approved medications for their treatment. At the ACR Convergence 2021 annual Review Course, Kristin Highland, MD, MSCR, director of the Rheumatic Lung Disease Program at the Cleveland Clinic, provided an exceptional overview of this topic and future developments to expect in the field.

Significant Source of Morbidity & Mortality

Dr. Highland

Dr. Highland began by noting that CTD-ILD can be prevalent in certain rheumatic diseases and can represent a significant source of morbidity and mortality. In scleroderma, autopsy studies have demonstrated the presence of ILD in 75–95% of patients and, although scleroderma renal crisis was the leading cause of death in patients in the early 1970s, pulmonary fibrosis became the leading cause of mortality in patients with scleroderma by the early 2000s.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In patients with rheumatoid arthritis, the prevalence of ILD is estimated to be 5–58%, with a 7.7% lifetime risk of developing this condition, which can precede articular disease in up to 20% of patients and is responsible for 10–20% of deaths.2,3

 Radiographic Pattern of Disease

Once ILD has been identified in a patient, Dr. Highland explained that it is important to understand the radiographic pattern of disease to predict prognosis. Nonspecific interstitial pneumonia combines reticulations and ground glass opacities that tend to be peripheral with an apical to basilar gradient. This is the most common pattern of ILD seen in connective tissue diseases. The presence of ground glass opacities implies inflammatory changes that are potentially reversible. Such findings may also be seen with organizing pneumonia, particularly in patients with rheumatoid arthritis, lupus and idiopathic inflammatory myopathies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In contrast, lymphocytic interstitial pneumonitis, most often seen in patients with Sjögren’s syndrome, and interstitial pneumonia, which can be seen in patients with idiopathic pulmonary fibrosis and rheumatoid arthritis, are fibrotic conditions that are not typically reversible with immunosuppression.

Dr. Highland showed that by combining knowledge of the pattern of ILD seen on high-resolution computed tomography (CT) imaging, the forced vital capacity (FVC) as determined by pulmonary function testing and the histopathologic pattern of disease seen on lung biopsy, patients can be grouped into subsets of CTD-ILD and survival rates can be predicted with reasonable accuracy.

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Sclerosis Tagged with:ACR Convergence 2021connective tissue diseaseinterstitial lung disease (ILD)nintedanib

Related Articles

    What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

    December 1, 2012

    Patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing connective tissue disease-associated interstitial lung disease (CTD-ILD)
     

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients

    February 15, 2017

    SAN FRANCISCO—Interstitial lung disease (ILD) represents a heterogeneous group of disorders characterized by inflammation or fibrosis of the lungs. The disorders are also associated with a spectrum of connective tissue diseases (CTDs). ILD is a common manifestation of CTDs, such as scleroderma, poly-/dermatomyositis and rheumatoid arthritis—and is a leading cause of morbidity and mortality in…

    Summit on Connective Tissue Disease-Associated ILD Fosters Interdisciplinary Dialogue

    May 6, 2019

    During an international summit, physicians and researchers discussed the key clinical and research aspects of the complex intersection between connective tissue diseases and interstitial lung disease (ILD), proposing initiatives to raise awareness and conduct research to better serve patients with autoimmune forms of ILD…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences